earningsconfidence high
Tonix Q1 net loss $40.2M; TONMYA launch generates $3.7M revenue with 2,145 prescribers
Tonix Pharmaceuticals Holding Corp.
2026-Q1 EPS
reported -$2.93
vs consensus -$2.48
▼ miss
(-18.0%)
- Net product revenue $6.9M (TONMYA $3.7M, legacy products $3.2M); net loss $40.2M ($2.93/share).
- Cash $185.5M at Mar 31; raised $22.6M post-quarter via ATM; runway into early Q2 2027.
- TONMYA Q1: 2,145 HCPs prescribed, 3,588 patients initiated, ~5,400 Rx; cumulative 11,016 Rx through May 1.
- Secured GPO agreement covering ~35M commercial lives; Medicaid coverage in 38 states (~55M lives).
- TNX-4800 Phase 2 Lyme prevention study planned for 2027; TNX-102 SL MDD Phase 2 to start mid-2026.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.